Kyrgyzstan Periodic Safety Reporting: Continuous Surveillance of Safety, Quality and Effectiveness

1. Key takeaways

Kyrgyzstan applies continuous surveillance to registered devices: Annex 2 to Cabinet Resolution No. 513 establishes the Procedure for Monitoring the Safety, Quality and Effectiveness of Medical Devices, and the objects of surveillance are precisely the three attributes of safety, quality and effectiveness — the very same objects assessed in the expert appraisal at the registration stage. This correspondence is the key to designing a post-market system in this market: the questions that surveillance must keep answering after market entry are the same questions that were asked before it.

2. Legal basis

1. Cabinet Resolution No. 513, August 27, 2024, Annex 2: the Procedure for Monitoring the Safety, Quality and Effectiveness of Medical Devices.
2. Article 1(1) of Cabinet Resolution No. 513: the objects of appraisal under Annex 1 are safety, effectiveness and quality.
3. Article 14 of Law No. 216: foreign products must obtain a positive expert appraisal of safety, quality and effectiveness, taking into account the potential risk level.
4. Article 15 of Law No. 216: the emergence of new systematic data indicating that risks outweigh benefits constitutes a ground for revocation of the registration certificate.
5. Cabinet Resolution No. 450, June 29, 2026: procedures for inspections in the distribution stage.

Source note: the specific cycles, formats and submission methods for periodic reporting were not available this round in official wording suitable for verbatim citation. This article therefore does not state a specific reporting cycle; the original text of Annex 2 to Cabinet Resolution No. 513 prevails.

3. Expert insights

Insight one: before market entry and after market entry, the same set of questions is being answered.

Placing Article 14 (a positive expert appraisal of safety, quality and effectiveness is required for registration) side by side with Annex 2 (post-market surveillance of safety, quality and effectiveness) reveals a clear correspondence:

• Safety: demonstrated before market entry through testing and clinical evidence; verified continuously after market entry through adverse event and vigilance data;
• Effectiveness: demonstrated before market entry through clinical and clinical laboratory testing; verified continuously after market entry through clinical feedback and complaint data;
• Quality: demonstrated before market entry through technical testing and the quality system; verified continuously after market entry through batch consistency, returns and quality problem data.

This correspondence can be used directly as the design framework for surveillance indicators.

Insight two: systematic data is the hinge connecting surveillance to the survival of the registration certificate.

Article 15 lists the emergence of new systematic data indicating that risks outweigh benefits as a ground for revocation. The word systematic matters — isolated individual events usually do not trigger it, but once events of the same kind accumulate into a pattern, the nature of the situation changes. This means a surveillance system must be capable of recognizing patterns, not merely collecting individual cases. We recommend quarterly trend analysis rather than case-by-case handling.

Insight three: the continuous nature of surveillance offsets the indefinite validity of the registration certificate.

Registration certificates are issued without an expiry date (Article 15); the surveillance obligation, in turn, is continuous and has no end point. The combined result is that the certificate does not lapse automatically, but it can lapse because of data. Companies should therefore manage certificate status and surveillance data status on a single dashboard rather than separately.

Insight four: surveillance data is an input to change and improvement.

Quality problems identified through surveillance often translate into product improvements or labeling changes. Changes require review and approval, and after 2028 they can only be handled under the Union rules. This creates a chain: surveillance finding → change need → change application → pathway constraints. We recommend building this chain into annual compliance planning so that improvement needs arising from surveillance do not get stuck at the pathway stage.

Insight five: surveillance records are among the most frequently requested materials during inspections.

Cabinet Resolution No. 450 extends inspections into the distribution stage, and surveillance records are a core material in that context. We recommend maintaining records to a standard of immediate retrievability rather than assembling them hastily for an inspection.

4. Practical recommendations

First, design surveillance indicators along the three dimensions of safety, effectiveness and quality. We recommend setting concrete indicators for each dimension: safety (adverse event counts and severity distribution), effectiveness (clinical feedback and performance complaints), and quality (batch rejection rates, return rates, transport damage rates).

Second, establish a quarterly trend analysis mechanism. We recommend analyzing trends across the three indicator sets every quarter to determine whether a systematic pattern is emerging, and retaining the analysis reports.

Third, place certificate status and surveillance data status on the same dashboard. We recommend presenting in parallel in management reports: registration certificate status, dossier change status, surveillance indicator trends, and pending change items.

Fourth, bring improvement needs identified through surveillance into change planning. We recommend consolidating surveillance-driven improvement needs with the change plan in annual compliance planning, factoring in the December 31, 2028 pathway constraint.

Fifth, maintain surveillance records to a standard of immediate retrievability. We recommend a standardized archive structure, held by the authorized representative and updated quarterly.

5. Verification checklist

• □ Surveillance indicators have been designed along the three dimensions of safety, effectiveness and quality;
• □ A quarterly trend analysis mechanism is in place to identify systematic patterns, with analysis reports retained;
• □ Management reports present in parallel: registration certificate status, dossier change status, surveillance indicator trends, and pending change items;
• □ Improvement needs identified through surveillance have been incorporated into change planning, factoring in the December 31, 2028 pathway constraint;
• □ Surveillance records are maintained to a standard of immediate retrievability, held by the authorized representative and updated quarterly;
• □ The original text of Annex 2 to Cabinet Resolution No. 513 has been obtained to verify the cycles and formats of periodic reporting.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system conformity support, post-market surveillance and vigilance system setup, import and distribution compliance, and fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations and has built stable local cooperation networks in Bishkek, Almaty, Tashkent and Moscow. Working in Chinese, Russian and English, we deliver actionable solutions for foreign manufacturers on the key issues commonly encountered in CIS markets, including authorized representative arrangements, notarization and legalization chains for powers of attorney, localization of technical documentation, and inspection readiness.

We hold to one principle: every regulatory conclusion we publish must be traceable to verifiable official sources; figures and timelines that cannot be verified are always marked as practical estimates and are never presented as legal requirements drawn from experience.

GRZAN provides registration and compliance support in this country for manufacturers, importers and authorized representatives. For project inquiries on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Regulatory Registration and Compliance Services for Medical Devices